4.7 Article

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Journal

VACCINES
Volume 10, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/vaccines10010086

Keywords

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); booster; third dose; inactivated vaccine; viral vector vaccine; mRNA vaccine; clinical trial

Funding

  1. Health Systems Research Institute (HSRI)
  2. National Research Council of Thailand (NRCT)
  3. Center of Excellence in Clinical Virology, Chulalongkorn University
  4. King Chulalongkorn Memorial Hospital
  5. Second Century Fund (C2F)

Ask authors/readers for more resources

This study evaluated the booster effect of different vaccine platforms in healthy adults who had received a full dose of inactivated vaccine. The viral vector and mRNA vaccine boosters showed greater immunogenicity compared to the inactivated vaccine. In addition, the vaccinated serum had a high neutralization activity against SARS-CoV-2 wild-type and variants.
The coronavirus disease 2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2), in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7-alpha, B.1.351-beta, and B.1.617.2-delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of IFN-gamma secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available